This is an aggregated industry headline. Read the full story at FiercePharma →
Fierce Pharma Asia-Astellas CEO's 5-year plan; Takeda's psoriasis win; RA's China bridge program
Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a one-year-old initiative. And more.
By FiercePharma
· Jun 15, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfo…
The WeekFierceBiotech ↗
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a de…
The WeekBriefing
CMS’s proposed 2027 OPPS rule would cut 340B drug reimbursement from ASP plus 6% to ASP minus 33.4%. The savin…